These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6102427)

  • 1. Plasma neuroleptic and prolactin levels in mentally retarded patients.
    Linnolia M; Viukari M; Vaisanen K; Auvinen J
    Acta Pharmacol Toxicol (Copenh); 1980 Feb; 46(2):159-60. PubMed ID: 6102427
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of anticonvulsants on plasma haloperidol and thioridazine levels.
    Linnoila M; Viukari M; Vaisanen K; Auvinen J
    Am J Psychiatry; 1980 Jul; 137(7):819-21. PubMed ID: 6770696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients.
    Rao ML; Brown WA
    Psychopharmacology (Berl); 1987; 93(2):237-42. PubMed ID: 2892222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesoridazine and thioridazine: clinical effects and blood levels in refractory schizophrenics.
    Vital-Herne J; Gerbino L; Kay SR; Katz IR; Opler LA
    J Clin Psychiatry; 1986 Jul; 47(7):375-9. PubMed ID: 2873133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations.
    Greendyke RM; Kanter DR
    J Clin Psychopharmacol; 1987 Jun; 7(3):178-82. PubMed ID: 3597804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients.
    Shvartsburd A; Sajadi C; Morton V; Mirabi M; Gordon J; Smith RC
    J Clin Psychopharmacol; 1984 Aug; 4(4):194-8. PubMed ID: 6470190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between psychotropic drug dosage, plasma drug concentration, and prolactin levels in nursing home residents.
    Cohen-Mansfield J; Taylor L; Woosley R; Lipson S; Werner P; Billig N
    Ther Drug Monit; 2000 Dec; 22(6):688-94. PubMed ID: 11128236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological treatment of self-injurious behavior in mentally retarded persons.
    Singh NN; Millichamp CJ
    J Autism Dev Disord; 1985 Sep; 15(3):257-67. PubMed ID: 2863252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity.
    Llerena A; Berecz R; de la Rubia A; Norberto MJ; Benítez J
    Ther Drug Monit; 2000 Aug; 22(4):397-401. PubMed ID: 10942178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation of a possible new metabolite of thioridazine and mesoridazine from human plasma.
    Dinovo EC; Gottschalk LA; Noble EP; Biener R
    Res Commun Chem Pathol Pharmacol; 1974 Mar; 7(3):489-96. PubMed ID: 4824823
    [No Abstract]   [Full Text] [Related]  

  • 11. Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients.
    Dorado P; Peñas-LLedó EM; de la Rubia A; LLerena A
    Pharmacogenomics; 2009 Jul; 10(7):1083-9. PubMed ID: 19604081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma level monitoring of antipsychotic drugs.
    Cooper TB
    Clin Pharmacokinet; 1978; 3(1):14-38. PubMed ID: 25154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical evaluation of mesoridazine in mentally retarded patients.
    Zaleski W
    Can Psychiatr Assoc J; 1970 Jun; 15(3):319-22. PubMed ID: 4913609
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.
    Carrillo JA; Ramos SI; Herraiz AG; Llerena A; Agundez JA; Berecz R; Duran M; Benítez J
    J Clin Psychopharmacol; 1999 Dec; 19(6):494-9. PubMed ID: 10587283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled double-blind study of haloperidol versus thioridazine in the treatment of restless mentally subnormal patients. Serum levels and clinical effects.
    Väisänen K; Rimón R; Räisänen P; Viukari M
    Acta Psychiatr Belg; 1979; 79(6):673-85. PubMed ID: 554446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the clinical relevance and methods of quantification of plasma concentrations of neuroleptics.
    Ko GN; Korpi ER; Linnoila M
    J Clin Psychopharmacol; 1985 Oct; 5(5):253-62. PubMed ID: 2864357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood level measurement of psychoactive drugs in pediatric psychiatry.
    Gualtieri CT; Golden R; Evans RW; Hicks RE
    Ther Drug Monit; 1984; 6(2):127-41. PubMed ID: 6146213
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of discontinuation of long-term used antipsychotics on prolactin and bone turnover markers in patients with intellectual disability.
    de Kuijper GM; Mulder H; Evenhuis H; Visser F; Hoekstra PJ
    J Clin Psychopharmacol; 2014 Feb; 34(1):157-9. PubMed ID: 24135841
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses.
    Salih IS; Thanacoody RH; McKay GA; Thomas SH
    Clin Pharmacol Ther; 2007 Nov; 82(5):548-54. PubMed ID: 17410120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood levels of neuroleptic drugs in nonresponding chronic schizophrenic patients.
    Smith RC; Crayton J; Dekirmenjian H; Klass D; Davis JM
    Arch Gen Psychiatry; 1979 May; 36(5):579-84. PubMed ID: 35115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.